Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 13, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 12, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 12, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact on January 09, 2026 Autoimmune cardiometabolic Eli Eli Lilly Immunotherapy for cancer InduPro * * Inflammatory disorder M&A Neoplasms Neuroinflammation NLRP3 inhibitors Obesity Ventyx Biosciences VTX3232 VTX958 +
Lilly to acquire Ventyx Biosciences for ~$1.2B to add oral NLRP3 and other inflammatory drugs on January 08, 2026 acquisition Autoimmune Diseases cardiometabolic Eli Eli Lilly Inflammatory disorder Neuroinflammation NLRP3 inhibitors oral therapies Ventyx Biosciences +